SOUVIEN THERAPEUTICS
Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
SOUVIEN THERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Address:
Salt Lake City, Utah, United States
Country:
United States
Status:
Active
Contact:
1 860 208 0042
Total Funding:
3.5 M USD
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Current Employees Featured
Investors List
Juvenescence
Juvenescence investment in Venture Round - Souvien Therapeutics
More informations about "Souvien Therapeutics"
Souvien Therapeutics - VentureRadar
Souvien Therapeutics is a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration. ... we …See details»
Juvenescence's Latest Venture, Souvien Therapeutics, Creating ...
May 28, 2019 Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with …See details»
Souvien Therapeutics - Funding, Financials, Valuation & Investors
Souvien Therapeutics is developing novel therapeutics to modulate critical epigenetic mechanisms associated with neurodegeneration. Search Crunchbase. ... How much funding …See details»
Juvenescence's Latest Venture, Souvien Therapeutics ... - BioSpace
May 28, 2019 About Souvien Therapeutics. Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms …See details»
Juvenescence's Latest Venture, Souvien Therapeutics, Creating ...
May 28, 2019 TORTOLA, British Virgin Islands--(BUSINESS WIRE)-- Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and …See details»
Juvenescence launches Souvien Therapeutics to …
Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and increase human longevity, is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating …See details»
Souvien Therapeutics - Crunchbase
Organization. Souvien Therapeutics . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies Section. …See details»
Souvien Therapeutics - BioCentury Company Profiles - BCIQ
May 28, 2019 Souvien Therapeutics - BioCentury Company Profiles for the biopharma industrySee details»
Our Pipeline - Juvenescence
CORE MEDICINES PIPELINE Leading Healthspan Innovations Our core medicines (JuvTherapeutics) are comprised of therapeutics developed by the Juvenescence team, …See details»
Juvenescence Creates AI-Focused Approach to Longevity
In May, Juvenescence launched a new company called Souvien Therapeutics with $3.5 million based on the research of Li-Huei Tsai, the director of The Picower Institute for Learning and Memory at MIT. Souvien will create drugs to …See details»
Juvenescence :'s Latest Venture, Souvien Therapeutics, Creating ...
May 28, 2019 Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and increase human longevity, is pleased to announce its latest …See details»
Juvenescence closes $100m series B round for longevity therapies
Souvien Therapeutics is working on neurodegeneration therapeutics, BYOMass on ageing and age-related chronic illnesses candidates and BHB Therapeutics on ketosis-based approaches …See details»
Juvenescence Completes $100 Million Series B Financing Round
Aug 27, 2019 It recently formed a joint venture with the Buck Institute focused on inducing ketosis and is partnering with AI company Insilico Medicine. It has also started its own biotech …See details»
Juvenescence Raises $100 Million for Longevity Drug Development
Aug 19, 2019 Juvenescence, a company focused on developing treatments for diseases of aging and increasing human longevity, secured $100 million in a Series B financing round to …See details»
Souvien Therapeutics - Contacts, Employees, Board Members
Organization. Souvien Therapeutics . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Souvien …See details»
Jeff M Bio - Juvenescence
Dr. Jeff MadwedSenior Project Lead Jeff Madwed, PhD is currently Executive Director of the JuvRx Division at Juvenescence, a healthcare organization focused on developing products …See details»
Research programme: neurodegenerative disorder therapeutics
Neurodegenerative disorder therapeutics are being developed by Souvien Therapeutics for treatment of neurodegenerative disorders. These therapeutics will be Research programme: …See details»
A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves
S.J.H. is a member of the scientific advisory board of Psy Therapeutics, Frequency Therapeutics, Vesigen Therapeutics, 4M Therapeutics, and Sensorium Therapeutics, none of which is …See details»
Stoke Therapeutics Receives FDA Breakthrough Therapy ... - Nasdaq
1 day ago Stoke Therapeutics, Inc., a biotechnology company dedicated to restoring protein expression by harnessing the body’ s potential with RNA medicine, today announced that it …See details»